 Multiple Myeloma
"Multiple Myeloma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Descriptor ID |
D009101
|
| MeSH Number(s) |
C04.557.595.500 C14.907.454.460 C15.378.147.780.650 C15.378.463.515.460 C20.683.515.845 C20.683.780.650
|
| Concept/Terms |
Multiple Myeloma- Multiple Myeloma
- Multiple Myelomas
- Myelomas, Multiple
- Myeloma, Multiple
- Myeloma, Plasma-Cell
- Myeloma, Plasma Cell
- Myelomas, Plasma-Cell
- Plasma-Cell Myeloma
- Plasma-Cell Myelomas
- Myelomatosis
- Myelomatoses
- Plasma Cell Myeloma
- Cell Myeloma, Plasma
- Cell Myelomas, Plasma
- Myelomas, Plasma Cell
- Plasma Cell Myelomas
- Kahler Disease
- Disease, Kahler
- Myeloma-Multiple
- Myeloma Multiple
- Myeloma-Multiples
|
Below are MeSH descriptors whose meaning is more general than "Multiple Myeloma".
Below are MeSH descriptors whose meaning is more specific than "Multiple Myeloma".
This graph shows the total number of publications written about "Multiple Myeloma" by people in this website by year, and whether "Multiple Myeloma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 | | 1997 | 0 | 1 | 1 | | 2001 | 1 | 0 | 1 | | 2002 | 1 | 0 | 1 | | 2005 | 3 | 0 | 3 | | 2007 | 3 | 1 | 4 | | 2008 | 1 | 1 | 2 | | 2009 | 1 | 0 | 1 | | 2010 | 2 | 0 | 2 | | 2011 | 5 | 1 | 6 | | 2013 | 2 | 1 | 3 | | 2014 | 3 | 0 | 3 | | 2015 | 1 | 0 | 1 | | 2016 | 3 | 0 | 3 | | 2017 | 3 | 0 | 3 | | 2018 | 3 | 0 | 3 | | 2019 | 8 | 0 | 8 | | 2020 | 6 | 0 | 6 | | 2021 | 7 | 1 | 8 | | 2022 | 6 | 0 | 6 | | 2023 | 9 | 0 | 9 | | 2024 | 8 | 0 | 8 | | 2025 | 7 | 0 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Multiple Myeloma" by people in Profiles.
-
Rodr?guez-Lobato LG, de Daniel A, Pereira A, Fern?ndez de Larrea C, Tovar N, Cibeira MT, Moreno DF, Mateos JM, Llobet N, Carcelero E, Mun?rriz D, Blad? J, Rosi?ol L. Attrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period. Blood Cancer J. 2025 May 26; 15(1):103.
-
Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, Campagnaro E, Costello C, D'Angelo C, Derman B, Devarakonda S, Elsedawy N, Godara A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Robinson T, Rosenberg A, Schroeder MA, Sherbenou D, Suvannasankha A, Valent J, Varshavsky-Yanovsky AN, Vogl D, Kovach E, Kumar R. NCCN Guidelines? Insights: Multiple Myeloma, Version 1.2025. J Natl Compr Canc Netw. 2025 05; 23(5):132-140.
-
Dong S, Banerjee R, Khan AM, Wang M, Wang X, Afghahi A, Afrough A, Janakiram M, Wang B, Cowan AJ, Sperling AS, Anderson LD, Rajkumar SV, Kaur G. Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis. Blood Cancer J. 2025 Mar 28; 15(1):48.
-
Zugasti I, Tormo-Ratera M, Oliver-Cald?s A, Soler-Perromat JC, Gonz?lez-Calle V, Moreno DF, Caba?as V, L?pez-Mu?oz N, Bartolom?-Solanas ?, Espa?ol-Rego M, Reguera-Ortega JL, Rosi?ol L, L?pez-Corral L, Tovar N, Rodr?guez-Lobato LG, Alvarez Perez RM, Varea S, Olesti E, Gomez-Grande A, Frutos L, Tamayo P, Juan M, Moraleda JM, Urbano-Ispizua ?, Gonz?lez-Navarro EA, Mart?nez-L?pez J, Mateos MV, Tom?s X, Setoain X, Fern?ndez de Larrea C. Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma. Blood Adv. 2025 Feb 11; 9(3):571-582.
-
Battram AM, Ma??-Pujol J, Moreno DF, Oliver-Cald?s A, Carpio J, Cardus O, Rodr?guez-Lobato LG, Urbano-Ispizua ?, Fern?ndez de Larrea C. Genetic disruption of Blimp-1 drastically augments the antitumor efficacy of BCMA-targeting CAR T cells. Blood Adv. 2025 Feb 11; 9(3):627-641.
-
Varma G, Fogel L, Gordon B, Saldarriaga MM, Ahn J, Aleman A, Caro J, Rosenberg MC, Monge J, Parmar H, Kaminetzky D, Moskovits T, Siegel DS, Morgan GJ, Niesvizky R, Davies FE, Biran N. Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis. Leuk Lymphoma. 2025 May; 66(5):942-951.
-
Ohlstrom D, Walker ZJ, Pandey A, Davis LN, Engel KL, Pan Z, Forsberg PA, Mark TM, Gillen AE, Sherbenou DW. Single-Cell RNA Sequencing before and after Light Chain Escape Reveals Intrapatient Multiple Myeloma Subpopulations with Divergent Osteolytic Gene Expression. Cancer Res Commun. 2025 Jan 01; 5(1):106-118.
-
Derman BA, Major A, Cooperrider J, Jiang K, Ramsland A, Karrison T, Kubicki T, Jakubowiak AJ. Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024 10 07; 14(1):170.
-
Lozano E, Mena MP, Garrabou G, Card?s O, D?az T, Moreno DF, Ma??-Pujol J, Oliver-Cald?s A, Battram A, Tovar N, Cibeira MT, Rodr?guez-Lobato LG, Blad? J, Fern?ndez de Larrea C, Rosi?ol L. Increased PVR Expression on Bone Marrow Macrophages May Promote Resistance to TIGIT Blockade in Multiple Myeloma. Clin Cancer Res. 2024 Sep 03; 30(17):3944-3955.
-
Davis LN, Walker ZJ, Reiman LT, Parzych SE, Stevens BM, Jordan CT, Forsberg PA, Sherbenou DW. MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance. Clin Cancer Res. 2024 Jul 15; 30(14):3023-3035.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|